ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen

Wei, Jia; Zou, Zhengyun; Qian, Xiaoping; Ding, Yitao; Xie, Li; Sánchez, José Javier; Zhao, Yang; Feng, J.; Ye, Ling; Liu, Y; Yu, Lan; Rosell, Rafael; Liu, B

doi:10.1038/sj.bjc.6604317

Cited by 62 publications

(38 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, most of those studies focused on the influence of ERCC1 expression on the effect of platinum-drug in advanced or metastatic diseases, little was known about its effect on platinum-drug adjuvant chemotherapy. Our results suggested that low ERCC1 mRNA level appeared to be an independent prognostic factor for better prognosis, which is consistent with the results observed in advanced gastric cancer [30][31][32] .…”

Section: Discussionsupporting

confidence: 82%

“…In advanced gastric cancer patients treated with 5-FU and oxaliplatin, favorable response rate and survival were also found in patients without ERCC1 protein expression [7] . Other studies showed that the low intratumoral ERCC1 mRNA expression was associated with favorable clinical outcomes after treatment with platinum-based chemotherapy in lung cancer [27,28] , colorectal cancer [29] , gastric cancer [30][31][32] , ovarian cancer [33] , bladder cancer [34] , head and neck cancer [35] . A recent phase Ⅲ trial in nonsmall-cell lung cancer also demonstrated that assessment of intratumoral ERCC1 mRNA expression is feasible in the clinical setting and predicts response to cisplatin [36] .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer

Huang¹,

Dong²,

Du³

et al. 2008

WJG

View full text Add to dashboard Cite

in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy (P < 0.05).CONCLUSION: ERCC1 codon 118 polymorphism has no significant impact on ERCC1 mRNA expression, and the intratumoral ERCC1 mRNA level but not codon 118 polymorphism may be a useful predictive parameter for the relapse and survival of gastric cancer patients receiving oxaliplatin-based adjuvant chemotherapy. INTRODUCTIONIn China, gastric cancer is the leading cause of cancer deaths, accounting for nearly one-fourth of all cancer deaths. Surgery is the primary modality for managing early-stage and locally-advanced disease. However, even after gastrectomy, the majority of patients develop local or distant recurrence [1] . Adjuvant chemotherapy for gastric cancer has been under clinical investigation for more than four decades. Fluoropyrimidines, platinumdrugs and taxanes were shown to be effective in the treatment of gastric cancer. However, the response rates of these drugs or their combinations were less than 50% [2,3] . There is no standard regimen for postoperative treatment at the moment. Having an effective assay to predict the response to a given chemotherapeutic protocol beforehand would greatly enhance the success rate as well as the life quality of the patients.The nucleotide excision repair (NER) system plays a significant role in repairing a variety of distorting Abstract AIM: To determine the influence of excision repair cross complementing group 1 (ERCC1 ) codon 118 polymorphism and mRNA level on the clinical outcome of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. METHODS: Eighty-nine gastric cancer patients treated with oxalipatin-based adjuvant chemotherapy were included in this study. ERCC1 codon 118 C/T polymorphism was tested by polymerase chain reaction-ligation detection reaction (PCR-LDR) method in peripheral blood lymphocytes of those patients; and the intratumoral ERCC1 mRNA expression was measured using reverse transcription PCR in 62 patients whose tumor tissue specimens were available. RESULTS: No significant relationship was found between ERCC1 codon 118 polymorphism and ERCC1 mRNA level. The median relapse-free and overall survival period was 20.1 mo and 28.4 mo, respectively. The relapse-free and overall survivals in patients with low levels of ERCC1 mRNA were significantly longer than those in patients with high levels (P < 0.05), while there was no significant association found between ERCC1 118 genotypes and the disease prognosis. Multivariate analysis also showed that ERCC1 mRNA level was a potential predictor for relapse and survival

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer

Huang¹,

Dong²,

Du³

et al. 2008

WJG

View full text Add to dashboard Cite

show abstract

“…Later studies confirmed the predictive role of ERCC1 in NSCLC [12,37] and other types of cancer, such as colorectal cancer [17], gastric carcinoma [16,[38][39], and esophageal cancer [40]. Our study showed that patients with lower expression of ERCC1 had relatively higher DCR than patients with higher gene expression when they received platinum-based chemotherapy, which is consistent with previous studies.…”

Section: Discussionsupporting

confidence: 82%

Individualized treatment of NSCLC: From research to clinical practice

Zd²,

Lm³

et al. 2013

neo

View full text Add to dashboard Cite

The exact clinical significance of EGFR mutation status in NSCLC at the time of initial diagnosis remains disputable. The gene expression module in NSCLC for chemotherapy outcome prediction needs to be developed. We analyzed 56 patients with NSCLC received chemotherapy either with (n=20) or without EGFR-TKIs (n=36) between 2008 and 2012 in China. EGFR mutation test and gene expression profiling were performed in samples obtained before medication treatment by liquidchip platform. Significant association (P = 0.028) was seen between EGFR mutation status before first-line chemotherapy and EGFR-TKIs treatment outcomes, which even can be found from the status before second-or third-line treatment. A 14-gene expression profiling had been studied. Patients with low mRNA expression of ERCC1 or TYMS preferred higher DCR to cisplatin and pemetrexed than those with high expression (P = 0.39 and P = 0.11). Highly co-expression of TUBB3 and STMN1 gene has associated with the resistance to antimicrotubule drugs (P = 0.03). Our data suggest the EGFR mutations status, even at the time of initial diagnosis, is predictive of outcomes of TKIs treatment after chemotherapy. The mRNA expression profiling investigated in this study has a predictive value in NSCLC treatment, but further research with expanded samples is still required.

show abstract

“…Several studies have shown that expression of TS and ERCC1 has predictive value of response to chemotherapy and survival in advanced gastric cancer patients receiving systemic chemotherapy with 5-FU and platinum-based regimens [22][23][24][28][29][30][31]. Recently, Kwon et al reported a significant correlation between high expression of ERCC1 and poor survival in 64 advanced gastric cancer patients treated with FOLFOX using immunohistochemical staining [29].…”

Section: Discussionmentioning

confidence: 99%

Bax Predicts Outcome in Gastric Cancer Patients Treated with 5-fluorouracil, Leucovorin, and Oxaliplatin Palliative Chemotherapy

et al. 2010

View full text Add to dashboard Cite

Background Platinum and 5-fluorouracil (5-FU)-based regimens have been used the most frequently in palliative chemotherapy for gastric cancer. The present study evaluated the prognostic significance of Bax, excision repair cross-complementation group 1 (ERCC1), and thymidylate synthase (TS) in advanced gastric cancer patients treated with 5-FU, leucovorin, and oxaliplatin (FOLFOX) palliative chemotherapy. Methods Seventy-two patients with metastatic or recurrent gastric cancer were treated with FOLFOX regimen. Pretreatment tumor biopsy specimens were analyzed for Bax, ERCC1, and TS expression by immunohistochemistry.Results High expression of Bax, ERCC1, and TS was observed in 31 (43%), 33 (46%), and 35 (49%) patients, respectively. The median overall survival (OS) of patients was 12 months. Low expression of Bax was associated with poor OS (median, 9 months vs. 18 months; 2-year, 10% vs. 48%; p = 0.0005) in univariate analysis, while expression of ERCC1 and TS was not correlated with patient outcome. In multivariate analysis, low expression of Bax was a significant independent predictor of poor OS (p = 0.028). Low expression of Bax was significantly associated with poor survival of patients with metastatic or recurrent gastric cancer treated with FOLFOX chemotherapy. Conclusions Immunohistochemical staining for Bax with pretreatment biopsy specimen may be useful in selecting FOLFOX regimen as a treatment option for advanced gastric cancer patients.

show abstract

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen

Cited by 62 publications

References 36 publications

ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer

ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer

Individualized treatment of NSCLC: From research to clinical practice

Bax Predicts Outcome in Gastric Cancer Patients Treated with 5-fluorouracil, Leucovorin, and Oxaliplatin Palliative Chemotherapy

Contact Info

Product

Resources

About